Autopsy report · NCT03201159

A Pilot, Dose Escalating Study on VLX103 in Moderate Alcoholic Steatohepatitis

“Drug manufacturer ceased operations”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Gyongyi Szabo

Sponsor type

University, hospital or other

Conditions

Hepatic Steatosis

Interventions

VLX103

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
  “Manufacturer is no longer making the drug.” (80% match in meaning)
• Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)
  “Suspended due to lack of drug supply: the manufacturer ceased to provide investigational drug supply.” (72% match in meaning)
• The Study for Evaluate of Satety and Dfficacy of Hemostatic Device
  “The company stopped manufacturing the product” (71% match in meaning)
• Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer
  “Drug was no longer available” (70% match in meaning)
• TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
  “Drug no longer available” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.